227 related articles for article (PubMed ID: 17217815)
1. [Loss of heterozygosity on chromosome 3p in breast cancer and precancerous lesion].
Tang XL; Yao GY; Chen LR; Yang ZR; Li SL
Zhonghua Wai Ke Za Zhi; 2006 Oct; 44(19):1314-7. PubMed ID: 17217815
[TBL] [Abstract][Full Text] [Related]
2. Detailed deletion mapping of chromosome arm 3p in breast cancers: a 2-cM region on 3p14.3-21.1 and a 5-cM region on 3p24.3-25.1 commonly deleted in tumors.
Matsumoto S; Kasumi F; Sakamoto G; Onda M; Nakamura Y; Emi M
Genes Chromosomes Cancer; 1997 Nov; 20(3):268-74. PubMed ID: 9365834
[TBL] [Abstract][Full Text] [Related]
3. High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss.
Maitra A; Wistuba II; Washington C; Virmani AK; Ashfaq R; Milchgrub S; Gazdar AF; Minna JD
Am J Pathol; 2001 Jul; 159(1):119-30. PubMed ID: 11438460
[TBL] [Abstract][Full Text] [Related]
4. Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas.
Ingvarsson S; Agnarsson BA; Sigbjornsdottir BI; Kononen J; Kallioniemi OP; Barkardottir RB; Kovatich AJ; Schwarting R; Hauck WW; Huebner K; McCue PA
Cancer Res; 1999 Jun; 59(11):2682-9. PubMed ID: 10363992
[TBL] [Abstract][Full Text] [Related]
5. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
[TBL] [Abstract][Full Text] [Related]
6. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints.
Wistuba II; Behrens C; Virmani AK; Mele G; Milchgrub S; Girard L; Fondon JW; Garner HR; McKay B; Latif F; Lerman MI; Lam S; Gazdar AF; Minna JD
Cancer Res; 2000 Apr; 60(7):1949-60. PubMed ID: 10766185
[TBL] [Abstract][Full Text] [Related]
7. Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer.
Fullwood P; Marchini S; Rader JS; Martinez A; Macartney D; Broggini M; Morelli C; Barbanti-Brodano G; Maher ER; Latif F
Cancer Res; 1999 Sep; 59(18):4662-7. PubMed ID: 10493522
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands.
Ahmadian M; Wistuba II; Fong KM; Behrens C; Kodagoda DR; Saboorian MH; Shay J; Tomlinson GE; Blum J; Minna JD; Gazdar AF
Cancer Res; 1997 Sep; 57(17):3664-8. PubMed ID: 9288768
[TBL] [Abstract][Full Text] [Related]
9. Microsatellite alterations on human chromosome 11 in in situ and invasive breast cancer: a microdissection microsatellite analysis and correlation with p53, ER (estrogen receptor), and PR (progesterone receptor) protein immunoreactivity.
Shen KL; Yang LS; Hsieh HF; Chen CJ; Yu JC; Tsai NM; Harn HJ
J Surg Oncol; 2000 Jun; 74(2):100-7. PubMed ID: 10914818
[TBL] [Abstract][Full Text] [Related]
10. Loss of heterozygosity at 3p in benign lesions preceding invasive breast cancer.
Euhus DM; Maitra A; Wistuba II; Alberts A; Albores-Saavedra J; Gazdar AF
J Surg Res; 1999 May; 83(1):13-8. PubMed ID: 10210636
[TBL] [Abstract][Full Text] [Related]
11. Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast.
Lininger RA; Zhuang Z; Man Y; Park WS; Emmert-Buck M; Tavassoli FA
Mod Pathol; 1999 Dec; 12(12):1083-9. PubMed ID: 10619258
[TBL] [Abstract][Full Text] [Related]
12. Frequent FHIT gene loss of heterozygosity in human papillomavirus-infected non-smoking female lung cancer in Taiwan.
Wang J; Cheng YW; Wu DW; Chen JT; Chen CY; Chou MC; Lee H
Cancer Lett; 2006 Apr; 235(1):18-25. PubMed ID: 15935551
[TBL] [Abstract][Full Text] [Related]
13. [The loss of heterozygosity on the short arm of chromosome 3 in renal carcinoma].
Maestro de las Casas ML; del Barco Barriuso V; Moreno Sierra J; Izquierdo López L; Sanz Casla MT; Zanna I; Redondo González E; Chicharro Almarza J; Fernández Pérez C; Resel Estévez L
Arch Esp Urol; 1999; 52(1):3-9. PubMed ID: 10101881
[TBL] [Abstract][Full Text] [Related]
14. [Loss of heterozygosity on chromosome 3 in sporadic colorectal carcinoma].
Peng Z; Ling Y; Bai S
Zhonghua Yi Xue Za Zhi; 2001 Mar; 81(6):336-9. PubMed ID: 11798895
[TBL] [Abstract][Full Text] [Related]
15. Alterations of the FHIT gene in breast cancer: association with tumor progression and patient survival.
Ingvarsson S; Sigbjornsdottir BI; Huiping C; Jonasson JG; Agnarsson BA
Cancer Detect Prev; 2001; 25(3):292-8. PubMed ID: 11425271
[TBL] [Abstract][Full Text] [Related]
16. Pattern of chromosome 16q loss differs between an atypical proliferative lesion and an intraductal or invasive ductal carcinoma occurring subsequently in the same area of the breast.
Tsuda H; Takarabe T; Akashi-Tanaka S; Fukutomi T; Hirohashi S
Mod Pathol; 2001 May; 14(5):382-8. PubMed ID: 11353046
[TBL] [Abstract][Full Text] [Related]
17. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
[TBL] [Abstract][Full Text] [Related]
18. Fragile histidine triad gene abnormalities in the pathogenesis of gallbladder carcinoma.
Wistuba II; Ashfaq R; Maitra A; Alvarez H; Riquelme E; Gazdar AF
Am J Pathol; 2002 Jun; 160(6):2073-9. PubMed ID: 12057912
[TBL] [Abstract][Full Text] [Related]
19. Loss of heterozygosity on chromosomes 3, 9, 13, and 17, including the retinoblastoma locus, in uveal melanoma.
Scholes AG; Liloglou T; Maloney P; Hagan S; Nunn J; Hiscott P; Damato BE; Grierson I; Field JK
Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2472-7. PubMed ID: 11581185
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer.
Manderson EN; Presneau N; Provencher D; Mes-Masson AM; Tonin PN
Mol Carcinog; 2002 Jun; 34(2):78-90. PubMed ID: 12112314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
